???global.info.a_carregar???
Sofia Braga, MD, PhD is graduating from the Faculty of Medicine at the University of Lisbon. Her passion for advancing the fight against cancer led her to pursue a PhD in Clinical Decisions in Breast Cancer in 2014. Presently, Sofia stands as the Director of Oncology Service at the Professor Doctor Fernando Fonseca Hospital, where she leads with unwavering dedication and expertise. In addition to her clinical responsibilities, Sofia plays an active role in research activities at NOVA Medical School, being affiliated with the Translational Tumor Immunology Lab and Tissue Repair and Inflammation Lab.
Identification

Personal identification

Full name
Sofia Azambuja Duarte Santos Braga

Citation names

  • Braga, Sofia

Author identifiers

Ciência ID
3F1C-792B-93F2

Addresses

  • NOVA Medical School, Universidade NOVA de Lisboa . Rua Câmara Pestana, nº6, 1150-082, Lisboa, Lisboa, Portugal (Professional)
  • José de Mello Saúde, Av. do Forte nº 3, Edif. Suécia III, piso 2 , 2790-073 , Carnaxide, Oeiras, Portugal (Professional)

Websites

Knowledge fields

  • Medical and Health Sciences - Clinical Medicine - Oncology

Languages

Language Speaking Reading Writing Listening Peer-review
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Portuguese Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
French Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Spanish; Castilian Intermediate (B1) Intermediate (B1) Beginner (A1) Intermediate (B1)
Education
Degree Classification
2009 - 2014
Concluded
 Programa de Formação Médica Avançada (Fundação Gulbenkian) (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
"Clinical decisons in breast cancer a heterogenous disease" (THESIS/DISSERTATION)
 Aprovado por unanimidade
1992 - 1998
Concluded
 Medicina (Mestrado integrado)
Universidade de Lisboa Faculdade de Medicina, Portugal
 16
Affiliation

Teaching in Higher Education

Category
Host institution 		Employer
2016/01/01 - Current Assistant Professor (University Teacher) Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2009/03/01 - Current Assistant Professor (University Teacher) Universidade do Algarve - Campus de Gambelas, Portugal

Others

Category
Host institution 		Employer
2023/03 - Current Director Oncology Department Hospital Professor Doutor Fernando Fonseca EPE, Portugal
2016 - Current Research Collaborator Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2021 - 2024 Director Oncology Department Hospital CUF Cascais, Portugal
2021 - 2024 Director Oncology Department HOSPITAL CUF SINTRA, Portugal
2015/12/01 - 2023 Consultant Oncologist Hospital Professor Doutor Fernando Fonseca EPE, Portugal
2014/11/01 - 2021 Consultant Oncologist Hospital de Vila Franca de Xira, Portugal
2013/01/01 - 2021 Scientific Director Rede CUF, Portugal
2015 - 2015 Clinical Research iNOVA4Health, Portugal
2011/09/01 - 2012/12/31 Staff Oncologist Fundação Champalimaud, Portugal
2006/07/23 - 2011/10/01 Staff Oncologist Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2000/01/01 - 2006/07/21 Specialty training Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2005/05/01 - 2006/06/30 Clinical Research Fellow Institut Jules Bordet, Belgium
1998/01/01 - 2000/12/31 General residency Hospital de Santa Maria, Portugal
Projects

Grant

Designation Funders
2025 - Current Personalizing immunotherapy for high-risk early-stage triple negative Breast cancer by targeting immunosuppressive neutrophils
Bolsa da Liga Portuguesa Contra o Cancro
Researcher
Liga Portuguesa Contra o Cancro
Ongoing
2025 - Current Targeting Immunosuppressive Neutrophils: Unlocking new pathways in Immune Oncology to improve Triple Negative Breast Cancer treatments
26612
Researcher
Gilead Génese
Ongoing
2019 - 2021 Dissecting the predictive and therapeutic value of HLA-DR expressing T Lymphocytes in Breast Cancer.
Terry Fox Research Grant 2019
Researcher
Liga Portuguesa Contra o Cancro, Portugal
2019 - 2021 HLA-DR+T cell subsets as biomarkers of breast cancer aggressiveness and patients’ response to neoadjuvant chemotherapy.
Tagus Tank Consortium- Research Prize in Medicine 2018
Researcher
Tagus Tank Consortium, Portugal
2016 - 2020 Therapeutic Targets for Triple Negative Breast Cancer: Development of mono and bispecific antibodies against Notch1 ligands.
PTDC/BBB-BMD/4497/2014
Researcher
Fundação para a Ciência e a Tecnologia, Portugal
2016 - 2018 Searching positive biomarkers in Triple negative breast cancer (TNBC)
UID/Multi/04462/2013-Lisboa-01-0145FEDER-007
Researcher
Fundação para a Ciência e a Tecnologia, Portugal

iNOVA4Health, Portugal
2012 - 2014 Centrosome abnormalities in breast cancer
Terry Fox Award 2012
Researcher
Liga Portuguesa Contra o Cancro, Portugal
Concluded

Other

Designation Funders
2021 - 2022/12 Cracking the role and therapeutic value of novel CCR4+ low density neutrophils in breast cancer.
iNOVA4Health
Researcher
iNOVA4Health, Portugal
Outputs

Publications

Book chapter
  1. Braga, Sofia. "Cancro da mama triplo negativo". In 100 perguntas chave no cancro da mama. Permayer Portugal 2015, 2015.
    Published
Conference abstract
  1. Salvador, Rute; Correia, Bruna Filipa; Grosa, Daniela; Martins, Telma; Braga, Sofia; Jacinto, Antonio; Cabral, Maria Guadalupe. "Increasing HLA-DR-expressing Cytotoxic T lymphocytes as a novel approach to improve Breast Cancer therapy". Paper presented in 1st NMS Research Week, Lisbon, 2023.
Conference poster
  1. Telma Sofia Cipriano Martins; Correia, Bruna Filipa; Grosa, Daniela; Salvador, Rute; Brites, Inês; Xavier de Sousa, Carolina; Idília Pina; et al. "The Prognostic Value of Low Density Neutrophils in Breast Cancer: Implications for Therapeutic Strategies". Paper presented in ESMO Immuno-Oncology Congress 2024, 2024.
  2. Correia, Bruna F.; Grosa, Daniela; Salvador, Rute; Brites, Inês; Martins, Telma; Xavier de Sousa, Carolina; Idília Pina; et al. "Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter". Paper presented in ESMO Immuno-Oncology Congress 2024, 2024.
  3. Correia, Bruna Filipa; Grosa, Daniela; Salvador, Rute; Braga, Sofia; Telma Sofia Cipriano Martins; Jacinto, Antonio; Cabral, Maria Guadalupe. "Exploring the role and clinical relevance of a novel subset of immunosuppressive low density neutrophils in Breast Cancer". Paper presented in 1st NMS Research Week, 2023.
  4. Martins, Telma; Freitas R; Vitorino M; Machado M; Batista MV; Chaves A; Braga, Sofia. "Characteristics of BRCA-Positive Patients". Paper presented in 20º SPO Congress, 2023.
  5. Correia, BF; Salvador, Rute; Lobato da Rosa, João; Ana Sofia Cristóvão Ferreira; Braga, Sofia; Jacinto, Antonio; Cabral, MG. "Exploring new subsets of immunosuppressive neutrophils - targets to improve therapeutic strategies for metastatic breast cancer". Paper presented in XLVII SPI Annual Meeting 2022, 2022.
  6. Salvador, Rute; Diana P Saraiva; Correia, Bruna Filipa; Ana Sofia Cristóvão Ferreira; Braga, Sofia; Jacinto, Antonio; Cabral, Maria Guadalupe. "HLA-DR-expressing Cytotoxic T lymphocytes as a novel approach to improve Breast Cancer therapy". 2022.
  7. Correia, Bruna F; Salvador, Rute; Rosa, João L; Cristovão-Ferreira, Sofia; Braga, Sofia; Jacinto, António; Cabral, M Guadalupe. "Exploring new subsets of immunosuppressive neutrophils - Targets to improve therapeutic strategies for metastatic Breast Cance". Paper presented in XLVII Annual Meeting of the SPI, 2022.
  8. Correia BF; Saraiva DP; Salvador R; De Sousa N; Jacinto A; Braga S; Cabral MG. "Unveiling the clinical relevance of low density neutrophils in Breast Cancer patients.". Paper presented in AIMS Meeting, 2021.
  9. Correia BF; Saraiva DP; Salvador R; De Sousa N; Jacinto A; Braga S; Cabral MG.. "Low density neutrophils are associated with a worse prognosis in Breast Cancer.". Paper presented in iMed Conference 12.0, 2020.
  10. Saraiva DP, Antunes A, Azeredo-Lopes S, Jacinto S, Braga S and Cabral MG. "HLA-DRhigh cytotoxic T cells as a validated and independent predictive biomarker of breast cancer response to treatment and as a potential therapeutic approach.". Paper presented in Cancer Biology: From Basic to Translational Research, 2020.
  11. Vitorino, Marina; Santos, Catarina; Braga, Sofia. "200 Evaluation of a proposed trastuzumab biosimilar compared with trastuzumab in neoadjuvant breast cancer treatment". 2020.
    10.1136/ijgc-2020-esgo.1
  12. Saraiva, Diana P; Braga, Sofia; Jacinto, António; Cabral, Maria Guadalupe. "HLA-DR in cytotoxic and regulatory T cells dictates breast cancer aggressiveness and patient response to neoadjuvant chemotherapy.". Paper presented in 5th European Congress of Immunology, 2018.
  13. Saraiva, Diana P.; Braga, Sofia; Jacinto, António; Cabral, Maria Guadalupe. "HLA-DR expression in cytotoxic T Lymphocytes: A new predictor of Breast Cancer patients’ response to neoadjuvant chemotherapy.". Paper presented in XLIV Meeting of Portuguese Society of Immunology, 2018.
  14. Braga, Sofia. "Establishment of a prospective study to unveil the predictive value of breast cancer immune features in the response to neoadjuvant chemotherapy.". Paper presented in 4th Conference of translational medicine on pathogenesis and therapy of immune-mediated diseases, 2017.
  15. Lamy, Márcia; Ferreira, Andreia; Sales-Dias, Joana; Galvão, Joana; Braga, Sofia; Silva, Gabriela; Bandeiras, Tiago M.; Barbas, Ana. "Development of Novel Cancer Therapeutics for Breast Cancer: targeting Notch ligands Delta-like-1 and Jagged2". Paper presented in Inova4health meeting - Lisbon, Portugal, 2016.
  16. Sales-Dias, Joana; Lamy, Márcia; Ferreira, Andreia; Galvão, Joana; Braga, Sofia; Bandeiras, Tiago M.; Barbas, Ana. "The role of Notch ligand Delta-like 1 as a potential therapeutic target for the treatment of breast cancer". Paper presented in XIX National Congress of Biochemistry - Guimarães, Portugal, 2016.
  17. Braga, Sofia. "Heterogeneity of breast cancer". Paper presented in Canceromatics, Centro Nacional de Investigaciones Oncologicas, Madrid, 2011.
  18. Braga, Sofia. "Seven years of practice in counseling breast cancer families". Paper presented in European Society of Medical Oncology, 2008.
  19. Braga, Sofia. "Use of chemotherapy in the last three months of life". Paper presented in American Society of Clinical Oncology, 2005.
  20. Braga, Sofia. "Graft versus malignancy: Is it worth a second transplant?". Paper presented in European Bone Marrow Transplant Conference, 2005.
  21. Braga, Sofia. "Leucémia promielocítica aguda associada a carcinoma da mama. Uma descrição de quatro casos clínicos.". Paper presented in Reunião da Sociedade Portuguesa de Hematologia, 2005.
Journal article
  1. Bartsch, R.; Pérez-García, J.M.; Furtner, J.; Berghoff, A.S.; Marhold, M.; Starzer, A.M.; Hughes, M.; et al. "Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis". ESMO Open 10 1 (2025): 104092. https://doi.org/10.1016/j.esmoop.2024.104092.
    10.1016/j.esmoop.2024.104092
  2. Vaz Batista, Marta; Pérez-García, José Manuel; Garrigós, Laia; García-Sáenz, José Ángel; Cortez, Patricia; Racca, Fabricio; Blanch, Salvador; et al. "The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis". Med 6 1 (2025): 100502. https://doi.org/10.1016/j.medj.2024.08.001.
    10.1016/j.medj.2024.08.001
  3. Salvador, Rute; Correia, Bruna Filipa; Grosa, Daniela; Telma Sofia Cipriano Martins; Suelen Cristina Soares Baal; Diana P Saraiva; Ana Sofia Cristóvão Ferreira; et al. Corresponding author: Cabral, Maria Guadalupe. "HLA-DR expression in Cytotoxic T Lymphocytes is crucial for increasing the therapeutic potential of T cell-based strategies for Breast Cancer". Scientific Reports (2025):
    Under revision
  4. Vaz Batista, M.; Pérez-García, J.M.; Cortez, P.; Garrigós, L.; Fernández-Abad, M.; Gion, M.; Martínez-Bueno, A.; et al. "Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial". ESMO Open 9 9 (2024): 103699. https://doi.org/10.1016/j.esmoop.2024.103699.
    10.1016/j.esmoop.2024.103699
  5. Bowen, Joanne; Braga, Sofia; Zotto, Valeria Dal; Finnie, John; DiPrimeo, Daniel; Cooke, Blaire; Bischof, Georg F.; Wong, Alvin; Di Palma, Jack A.. "Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib-induced diarrhea in HER2-positive breast cancer—A pilot study". Physiological Reports 12 16 (2024): https://doi.org/10.14814/phy2.70008.
    10.14814/phy2.70008
  6. Gebhart, Geraldine; Keyaerts, Marleen; Guiot, Thomas; Flamen, Patrick; Ruiz-Borrego, Manuel; Stradella, Agostina; Bermejo, Begoña; et al. "Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial". Journal of Nuclear Medicine 65 5 (2024): 708-713. https://doi.org/10.2967/jnumed.123.266384.
    10.2967/jnumed.123.266384
  7. Pérez-García, José Manuel; Cortés, Javier; Ruiz-Borrego, Manuel; Colleoni, Marco; Stradella, Agostina; Bermejo, Begoña; Dalenc, Florence; et al. "3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial". The Lancet 403 10437 (2024): 1649-1659. https://doi.org/10.1016/s0140-6736(24)00054-0.
    10.1016/s0140-6736(24)00054-0
  8. Michelon, I.; Vilbert, M.; Marinho, A.D.; Castro, C.E.R.; Dacoregio, M.I.; Stecca, C.; Soares, L.R.; et al. "Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis". ESMO Open 9 2 (2024): 102233. http://dx.doi.org/10.1016/j.esmoop.2024.102233.
    10.1016/j.esmoop.2024.102233
  9. Duarte Mendes, Ana; Freitas, Ana Rita; Vicente, Rodrigo; Ferreira, Ricardo; Martins, Telma; Ramos, Maria João; Baptista, Carlota; et al. "Beta-Adrenergic Blockade in Advanced Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Multicentric Study". Cureus (2024): http://dx.doi.org/10.7759/cureus.52194.
    10.7759/cureus.52194
  10. Duarte Mendes, Ana; Freitas, Ana Rita; Vicente, Rodrigo; Vitorino, Marina; Vaz Batista, Marta; Silva, Michelle; Braga, Sofia. "Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?". International Journal of Molecular Sciences 24 23 (2023): 16589. http://dx.doi.org/10.3390/ijms242316589.
    10.3390/ijms242316589
  11. Batista, Marta Vaz; Perez-Garcia, José; Eiriz, Inês; Gion, Maria; Llombart, Antonio; Braga, Sofia; Cortés, Javier. "Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity". Annals of Translational Medicine 11 11 (2023): 398-398. http://dx.doi.org/10.21037/atm-23-1603.
    10.21037/atm-23-1603
  12. Gosalbez Pequeno, B.E.; Matos, A.L.V.; Nogal Dias, A.M.; Braga, S.; Pinto, L.I.; Pêgo, A.; Abreu, C.D.; et al. "451P Breast Cancer Lighthouse study: 1 year follow-up results of ribociclib treatment patterns and clinical outcomes in a real-world Portuguese cohort". Annals of Oncology 34 (2023): S371. https://doi.org/10.1016/j.annonc.2023.09.627.
    10.1016/j.annonc.2023.09.627
  13. Eiriz, Inês; Batista, Marta Vaz; Freitas, Ana Rita; Martins, Telma; Machado, Catarina; Braga, Sofia; Santos, Catarina. "PARP inhibitors in HRD BRCAness breast cancer patients". Journal of Cancer Biology 4 1 (2023): 17-28. http://dx.doi.org/10.46439/cancerbiology.4.049.
    10.46439/cancerbiology.4.049
  14. Pascoal, Carlota; Carrascal, Mylène A.; Barreira, Daniela F.; Lourenço, Rita A.; Granjo, Pedro; Grosso, Ana R.; Borralho, Paula; Braga, Sofia; Videira, Paula A.. "Sialyl LewisX/A and Cytokeratin Crosstalk in Triple Negative Breast Cancer". Cancers 15 3 (2023): 731. http://dx.doi.org/10.3390/cancers15030731.
    10.3390/cancers15030731
  15. Batista, Marta Vaz; Perez-Gracia, José; Eiriz, Inês; Gion, Maria; Llombart, Antonio; Braga, Sofia; Cortés, Javier. "Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?". Oncotarget 14 1 (2023): 701-702. http://dx.doi.org/10.18632/oncotarget.28435.
    10.18632/oncotarget.28435
  16. Vitorino, Marina; Eiriz, Inês; Tomás, Tiago C; Vicente, Rodrigo; Mendes, Ana; Freitas, Ana Rita; Alves-Vale, Catarina; et al. "Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer". Cureus (2023): http://dx.doi.org/10.7759/cureus.c91.
    10.7759/cureus.c91
  17. Pérez-García, José Manuel; Gebhart, Geraldine; Borrego, Manuel Ruiz; Schmid, Peter; Marmé, Frederik; Prat, Aleix; Dalenc, Florence; et al. "Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study". Future Oncology 18 33 (2022): 3677-3688. http://dx.doi.org/10.2217/fon-2022-0663.
    10.2217/fon-2022-0663
  18. Pérez-García, José Manuel; Vaz Batista, Marta; Cortez, Patricia; Ruiz-Borrego, Manuel; Cejalvo, Juan Miguel; de la Haba-Rodriguez, Juan; Garrigós, Laia; et al. "Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial". Neuro-Oncology 25 1 (2022): 157-166. http://dx.doi.org/10.1093/neuonc/noac144.
    10.1093/neuonc/noac144
  19. Campone, Mario; Neven, Patrick; Petrakova, Katarina; Braga, Sofia; Celanovic, Marina; Cohen, Patrick; Gosselin, Alice; et al. "Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer". Cancer Research 82 4_Suppleme (2022): OT2-11. https://doi.org/10.1158/1538-7445.sabcs21-ot2-11-02.
    10.1158/1538-7445.sabcs21-ot2-11-02
  20. Vitorino, Marina; Baptista de Almeida, Susana; Alpuim Costa, Diogo; Faria, Ana; Calhau, Conceição; Azambuja Braga, Sofia. "Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments". Frontiers in Oncology 11 (2022): http://dx.doi.org/10.3389/fonc.2021.815772.
    10.3389/fonc.2021.815772
  21. Batista, Marta Filipa Freire Vaz; Eiriz, Inês; Fitzpatrick, Amanda; Le Du, Fanny; Braga, Sofia; Alpuim Costa, Diogo. "Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis". Breast Care 17 6 (2022): 524-532. http://dx.doi.org/10.1159/000526431.
    10.1159/000526431
  22. Filipa Ferreira da Silva; Susana Baptista de Almeida; Maria de Lurdes Batarda; Braga, Sofia; Henrique Nabais. "Review of neoadjuvant chemotherapy characteristics in advanced epithelial ovarian cancer: experience from two cancer centers". European Journal of Gynaecological Oncology (2022): https://doi.org/10.22514/ejgo.2022.021.
    10.22514/ejgo.2022.021
  23. Saraiva, Diana P.; Correia, Bruna F.; Salvador, Rute; de Sousa, Nídia; Jacinto, António; Braga, Sofia; Cabral, M. Guadalupe. "Circulating low density neutrophils of breast cancer patients are associated with their worse prognosis due to the impairment of T cell responses". Oncotarget 12 24 (2021): 2388-2403. http://dx.doi.org/10.18632/oncotarget.28135.
    10.18632/oncotarget.28135
  24. Vaz Batista, M.; Pérez-Garcia, J.M.; Llombart Cussac, A.; Cortez, P.; Ruiz Borrego, M.; De La Haba, J.; Cejalvo, J.M.; et al. "330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH". Annals of Oncology 32 (2021): S509-S510. https://doi.org/10.1016/j.annonc.2021.08.613.
    10.1016/j.annonc.2021.08.613
  25. O'Shaughnessy, J.; Brufsky, A.; Rugo, H.S.; Tolaney, S.M.; Diab, S.; Punie, K.; Sardesai, S.; et al. "258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)". Annals of Oncology 32 (2021): S473-S474. https://doi.org/10.1016/j.annonc.2021.08.541.
    10.1016/j.annonc.2021.08.541
  26. Llombart Cussac, A.; Soberino, J.; Gion, M.; Bermejo, B.; Martinez- Garcia, M.; Braga, S.; Cardoso, F.; et al. "336TiP Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial". Annals of Oncology 32 (2021): S513. https://doi.org/10.1016/j.annonc.2021.08.619.
    10.1016/j.annonc.2021.08.619
  27. Da Cruz Tomas, T.F.; Eiriz, I.F.; Vitorino, M.; Vicente, R.S.; Mendes, A.D.; Sousa, M.C. Silva; Braga, S.; et al. "1602P COVID-19 vaccination efficacy in cancer patients: An ongoing prospective trial". Annals of Oncology 32 (2021): S1147. https://doi.org/10.1016/j.annonc.2021.08.1595.
    10.1016/j.annonc.2021.08.1595
  28. Batista, Marta Vaz; Alpuim Costa, Diogo; Borralho, Paula; Braga, Sofia. "Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time". Case Reports in Oncology 14 2 (2021): 1212-1219. http://dx.doi.org/10.1159/000517441.
    10.1159/000517441
  29. Silva, Gabriela; Sales-Dias, Joana; Casal, Diogo; Alves, Sara; Domenici, Giacomo; Barreto, Clara; Matos, Carolina; et al. "Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer". Cancers 13 16 (2021): 4074. http://dx.doi.org/10.3390/cancers13164074.
    10.3390/cancers13164074
  30. Saraiva, Diana P.; Azeredo-Lopes, Sofia; Antunes, Ana; Salvador, Rute; Borralho, Paula; Assis, Beatriz; Pereira, Isabel L.; et al. "Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer". Cancers 13 15 (2021): 3841. http://dx.doi.org/10.3390/cancers13153841.
    10.3390/cancers13153841
  31. Chandarlapaty, Sarat; Linden, Hannah M.; Neven, Patrick; Petrakova, Katarina; Bardia, Aditya; Kabos, Peter; Braga, Sofia A. D. S.; et al. "AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).". Journal of Clinical Oncology 39 15_suppl (2021): 1058-1058. https://doi.org/10.1200/jco.2021.39.15_suppl.1058.
    10.1200/jco.2021.39.15_suppl.1058
  32. Alpuim Costa, Diogo; Nobre, José Guilherme; Batista, Marta Vaz; Ribeiro, Catarina; Calle, Catarina; Cortes, Alfonso; Marhold, Maximilian; et al. "Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine". Frontiers in Microbiology 12 (2021): http://dx.doi.org/10.3389/fmicb.2021.584332.
    10.3389/fmicb.2021.584332
  33. Eiriz, Inês; Vitorino, Marina; Gomes, Fernando; Braga, Sofia. "Uterine Sarcomas: A Retrospective Analysis of a Cohort of 62 Patients". Cureus (2021): http://dx.doi.org/10.7759/cureus.13349.
    10.7759/cureus.13349
  34. Eiriz, I.F.; Vaz Batista, M.; Cruz Tomás, T.; Neves, M.T.; Guerra-Pereira, N.; Braga, S.. "Breast cancer in very young women—a multicenter 10-year experience". ESMO Open 6 1 (2021): 100029. http://dx.doi.org/10.1016/j.esmoop.2020.100029.
    10.1016/j.esmoop.2020.100029
  35. Alpuim Costa, Diogo; Nobre, José Guilherme; de Almeida, Susana Baptista; Ferreira, Marisa Horta; Gonçalves, Inês; Braga, Sofia; Pais, Diogo. "Cancer During Pregnancy: How to Handle the Bioethical Dilemmas?—A Scoping Review With Paradigmatic Cases-Based Analysis". Frontiers in Oncology 10 (2020): http://dx.doi.org/10.3389/fonc.2020.598508.
    10.3389/fonc.2020.598508
  36. Saraiva, Diana P.; Matias, Ana T.; Braga, Sofia; Jacinto, António; Cabral, M. Guadalupe. "Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies". Frontiers in Oncology 10 (2020): http://dx.doi.org/10.3389/fonc.2020.01543.
    10.3389/fonc.2020.01543
  37. Murthy, Rashmi K.; Loi, Sherene; Okines, Alicia; Paplomata, Elisavet; Hamilton, Erika; Hurvitz, Sara A.; Lin, Nancy U.; et al. "Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer". New England Journal of Medicine 382 7 (2020): 597-609. http://dx.doi.org/10.1056/nejmoa1914609.
    10.1056/nejmoa1914609
  38. Matias AT, Jacinta-Fernandes A, Maia AT, Braga S, Jacinto A, Cabral MG, Brito PH.. "Differential expression between African-ancestry and White patients diagnosed with Triple-Negative Breast Cancer: EGFR, Myc, Bcl2 and ß-Catenin as ancestry-associated markers.". bioRxiv (2020): 10.1101/2020.11.13.381608.
  39. Nogueira da Costa, G.; Eiriz, I.F.; Fernandes, I.G.; Batista, M.V.; Vicente, R.; Mendes, A.D.; Tomás, T.C.; Santos, C.C.; Braga, S.. "Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities". Annals of Oncology 30 (2019): ix85. http://dx.doi.org/10.1093/annonc/mdz426.025.
    10.1093/annonc/mdz426.025
  40. Saraiva, D.P.; Jacinto, A.; Braga, S.; Cabral, M.G.. "A 3D co-culture platform of breast cancer and patient derived immune cells to analyse the response to chemotherapy and immunotherapies". Annals of Oncology 30 (2019): v781. http://dx.doi.org/10.1093/annonc/mdz268.064.
    10.1093/annonc/mdz268.064
  41. Batista, M. Vaz; Tomás, T.C.; Eiriz, I.F.; Almeida, S.B.; Vitorino, M.; Atalaia, G.; del Rio, A.; Braga, S.. "Brain metastasis of breast cancer: A 10-year single institution retrospective analysis". Annals of Oncology 30 (2019): iii56. http://dx.doi.org/10.1093/annonc/mdz100.027.
    10.1093/annonc/mdz100.027
  42. Eiriz, I.F.; Pereira, N.G.; Neves, M.T.; Batista, M.V.; Tomás, T.C.; Braga, S.. "Breast cancer in young women: A multi-center 10-year experience". Annals of Oncology 30 (2019): iii32. http://dx.doi.org/10.1093/annonc/mdz096.015.
    10.1093/annonc/mdz096.015
  43. Saraiva, Diana P.; Jacinto, António; Borralho, Paula; Braga, Sofia; Cabral, M. Guadalupe. "HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy". Frontiers in Immunology 9 (2018): http://dx.doi.org/10.3389/fimmu.2018.02605.
    10.3389/fimmu.2018.02605
  44. Matias, A.T.; Jacinta-Fernandes, A.; Magno, R.; Xavier, J.; Cabral, M.G.; Jacinto, A.; Maia, A.T.; Braga, S.. "Differential molecular signature in patients from African origin with triple-negative breast cancer". Annals of Oncology 29 (2018): viii95. http://dx.doi.org/10.1093/annonc/mdy272.290.
    10.1093/annonc/mdy272.290
  45. Saraiva, D.P.; Jacinto, A.; Braga, S.; Cabral, M.G.. "A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells". Annals of Oncology 29 (2018): viii37-viii38. http://dx.doi.org/10.1093/annonc/mdy269.118.
    10.1093/annonc/mdy269.118
  46. Matias, A.T.; Jacinta-Fernandes, A.; Magno, R.; Xavier, J.; Cabral, M.G.; Jacinto, A.; Maia, A.T.; Braga, S.. "Differential molecular signature in patients from African origin with triple-negative breast cancer". Annals of Oncology 29 (2018): viii95. https://doi.org/10.1093/annonc/mdy272.290.
    10.1093/annonc/mdy272.290
  47. Rauh, Stefan; Arnold, Dirk; Braga, Sofia; Curca, Razvan; Eckert, Robert; Fröbe, Ana; Karamouzis, Michalis; Lakatos, Gabor; Molitor, Jean-Luc. "Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions". ESMO Open 3 5 (2018): e000385. http://dx.doi.org/10.1136/esmoopen-2018-000385.
    10.1136/esmoopen-2018-000385
  48. Carrascal, Mylène A.; Talina, Catarina; Borralho, Paula; Gonçalo Mineiro, A.; Henriques, Ana Raquel; Pen, Cláudia; Martins, Manuela; et al. "Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue". BMC Cancer 18 1 (2018): http://dx.doi.org/10.1186/s12885-018-4410-x.
    10.1186/s12885-018-4410-x
  49. Prager, Gerald W; Braga, Sofia; Bystricky, Branoslav; Qvortrup, Camilla; Criscitiello, Carmen; Esin, Ece; Sonke, Gabe S; et al. "Global cancer control: responding to the growing burden, rising costs and inequalities in access". ESMO Open 3 2 (2018): e000285. http://dx.doi.org/10.1136/esmoopen-2017-000285.
    10.1136/esmoopen-2017-000285
  50. Rauh, Stefan; Arnold, Dirk; Braga, Sofia; Curca, Razvan; Eckert, Robert; Fröbe, Ana; Karamouzis, Michalis; Lakatos, Gabor; Molitor, Jean-Luc. "Challenge of implementing clinical practice guidelines. Getting ESMO’s guidelines even closer to the bedside: introducing the ESMO Practising Oncologists’ checklists and knowledge and practice questions". ESMO Open 3 5 (2018): e000385. https://doi.org/10.1136/esmoopen-2018-000385.
    10.1136/esmoopen-2018-000385
  51. Lamy, Márcia; Ferreira, Andreia; Dias, Joana Sales; Braga, Sofia; Silva, Gabriela; Barbas, Ana. "Notch-out for breast cancer therapies". New Biotechnology 39 (2017): 215-221. http://dx.doi.org/10.1016/j.nbt.2017.08.004.
    10.1016/j.nbt.2017.08.004
  52. Saraiva, Diana P; Guadalupe Cabral, M; Jacinto, António; Braga, Sofia. "How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment". ESMO Open 2 4 (2017): e000208. http://dx.doi.org/10.1136/esmoopen-2017-000208.
    10.1136/esmoopen-2017-000208
  53. Atalaia, Gonçalo; Vaz Baptista, Marta; Tomás, Tiago; Almeida, Susana; Eiriz, Inês; Guerra, Nuno; Braga, Sofia; Del Rio, Ana; Fuiza, Teresa. "Prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). A 5 year retrospective analysis of our treated population.". Annals of Oncology 28 (2017): iii118-iii119. http://dx.doi.org/10.1093/annonc/mdx261.332.
    10.1093/annonc/mdx261.332
  54. Braga, Sofia; Cardoso, Joana; Andre, Saudade; Brito, Margarida; Sanchez, Pedro; Orvalho, Lurdes; Salgado, Lucilia; et al. "Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?". Current Cancer Drug Targets 17 1 (2016): 62-73. http://dx.doi.org/10.2174/1568009616666161025114914.
    10.2174/1568009616666161025114914
  55. Da Costa, Filipa Alves; Ribeiro, Manuel Castro; Braga, Sofia; Carvalho, Elisabete; Francisco, Fátima; Miranda, Ana Da Costa; Moreira, António; Fallowfield, Lesley. "Sexual Dysfunction in Breast Cancer Survivors: Cross-Cultural Adaptation of the Sexual Activity Questionnaire for Use in Portugal". Acta Médica Portuguesa 29 9 (2016): 533. http://dx.doi.org/10.20344/amp.7389.
    10.20344/amp.7389
  56. Cardoso, Fatima; van’t Veer, Laura J.; Bogaerts, Jan; Slaets, Leen; Viale, Giuseppe; Delaloge, Suzette; Pierga, Jean-Yves; et al. "70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer". New England Journal of Medicine 375 8 (2016): 717-729. http://dx.doi.org/10.1056/nejmoa1602253.
    10.1056/nejmoa1602253
  57. Honorio, Marta; Guerra Pereira, Nuno; Braga, Sofia. "Decreased Survival in African Patients with Triple Negative Breast Cancer". Journal of Palliative Care & Medicine 06 04 (2016): http://dx.doi.org/10.4172/2165-7386.1000270.
    10.4172/2165-7386.1000270
  58. Braga, Sofia. "Resistance to Targeted Therapies in Breast Cancer.". Methods in Molecular Biology (2016):
    Published
  59. Braga, Sofia. "Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model.". Methods in molecular biology (2016):
    Published
  60. Barbas, Ana; Lamy, Marcia; Ferreira, Andreia; Galvao, Joana; Braga, Sofia; Bandeiras, Tiago; Silva, Gabriela. "Development of novel biotherapeutics for breast cancer: generation of function blocking antibodies against Notch1 ligands". New Biotechnology (2016): https://publons.com/wos-op/publon/43912251/.
    10.1016/J.NBT.2016.06.889
  61. Guerra Pereira, Nuno; Braga, Sofia. "Is Breast Cancer Treatment in the End of Life Less Aggressive?". Journal of Palliative Care & Medicine 04 05 (2014): http://dx.doi.org/10.4172/2165-7386.1000194.
    10.4172/2165-7386.1000194
  62. Baselga, José; Gómez, Patricia; Greil, Richard; Braga, Sofia; Climent, Miguel A.; Wardley, Andrew M.; Kaufman, Bella; et al. "Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer". Journal of Clinical Oncology 31 20 (2013): 2586-2592. http://dx.doi.org/10.1200/jco.2012.46.2408.
    10.1200/jco.2012.46.2408
  63. Machado, Manuel; Braga, Sofia. "Reasons for Prophylactic Mastectomy in Women Carrying BRCA 1/2 Mutation: A Systematic Literature Review". Advances in Breast Cancer Research 02 03 (2013): 97-105. http://dx.doi.org/10.4236/abcr.2013.23017.
    10.4236/abcr.2013.23017
  64. Braga, Sofia. "Why do we treat lung cancer patients with chemotherapy until the end of life?". Journal of Thoracic Oncology 8 (2013):
    Published
  65. Cardoso, J.; Mesquita, M.; Braga, S.; Dias Pereira, A.; Bettencourt-Dias, M.; Chaves, P.; Pereira-Leal, J.. "1188 WWTR1 and CYR61 Are Early Prognostic Markers of Barrett's Esophagus Malignant Progression". European Journal of Cancer 48 (2012): S286. http://dx.doi.org/10.1016/s0959-8049(12)71782-3.
    10.1016/s0959-8049(12)71782-3
  66. Braga, S.. "Why do our patients get chemotherapy until the end of life?". Annals of Oncology 22 11 (2011): 2345-2348. http://dx.doi.org/10.1093/annonc/mdr416.
    10.1093/annonc/mdr416
  67. Oliveira, Mafalda; Braga, Sofia; Passos-Coelho, José Luís; Fonseca, Ricardo; Oliveira, João. "Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab". Breast Cancer Research and Treatment 127 3 (2011): 841-844. http://dx.doi.org/10.1007/s10549-011-1417-2.
    10.1007/s10549-011-1417-2
  68. Braga, Sofia. "Intrathecal trastuzumab in leptomeningeal and central nervous system metastases from HER2+ breast cancer: What if we could bypass the blood–brain barrier?". European Journal of Cancer (2010):
    Published
  69. Braga, Sofia. "Screening of the Portuguese BRCA2 Founder Mutation in Breast Cancer Patients Unselected for Family History.". Cancer Research 69 24 (2009):
    Published
  70. Leyland-Jones, Brian R.; Ambrosone, Christine B.; Bartlett, John; Ellis, Matthew J.C.; Enos, Rebecca A.; Raji, Adekunle; Pins, Michael R.; et al. "Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical Trials". Journal of Clinical Oncology 26 34 (2008): 5638-5644. http://dx.doi.org/10.1200/jco.2007.15.1712.
    10.1200/jco.2007.15.1712
  71. Ismael, Gustavo; Rosa, Daniela Dornelles; de Azambuja, Evandro; Braga, Sofia; Piccart-Gebhart, Martine. "Trastuzumab (Herceptin) for Early-Stage Breast Cancer". Hematology/Oncology Clinics of North America 21 2 (2007): 239-256. http://dx.doi.org/10.1016/j.hoc.2007.03.003.
    10.1016/j.hoc.2007.03.003
  72. Braga, Sofia; Miranda, Ana; Fonseca, Rute; Passos-Coelho, J. L.; Fernandes, Aires; Costa, J. D.; Moreira, António. "The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis". Psycho-Oncology 16 9 (2007): 863-868. http://dx.doi.org/10.1002/pon.1140.
    10.1002/pon.1140
  73. Mano, M. S.; Rosa, D. D.; Azambuja, E.; Ismael, G.; Braga, S.; D'HONDT, V.; Piccart, M.; Awada, A.. "Current management of ovarian carcinosarcoma". International Journal of Gynecologic Cancer 17 2 (2007): 316-324. http://dx.doi.org/10.1111/j.1525-1438.2006.00760.x.
    10.1111/j.1525-1438.2006.00760.x
  74. Rosa, Daniela D.; Ismael, Gustavo F.V.; de Azambuja, Evandro; Braga, Sofia; Cardoso, Fatima; Bleiberg, Harry. "OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy". Journal of Clinical Oncology 24 32 (2006): 5176-5177. http://dx.doi.org/10.1200/jco.2006.07.5630.
    10.1200/jco.2006.07.5630
  75. Bogaerts, Jan; Cardoso, Fatima; Buyse, Marc; Braga, Sofia; Loi, Sherene; Harrison, Jillian A; Bines, Jacques; et al. "Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial". Nature Clinical Practice Oncology 3 10 (2006): 540-551. http://dx.doi.org/10.1038/ncponc0591.
    10.1038/ncponc0591
  76. CARDOSO, F.; DAL LAGO, L.; BRAGA, S.. "Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself". International Journal of Gynecological Cancer 16 s2 (2006): 533-537. http://dx.doi.org/10.1111/j.1525-1438.2006.00690.x.
    10.1111/j.1525-1438.2006.00690.x
  77. Braga, Sofia; dal Lago, Lissandra; Bernard, Chantal; Cardoso, Fátima; Piccart, Martine. "Use of trastuzumab for the treatment of early stage breast cancer". Expert Review of Anticancer Therapy 6 8 (2006): 1153-1164. http://dx.doi.org/10.1586/14737140.6.8.1153.
    10.1586/14737140.6.8.1153
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2017/05 Fifteen years of practice changing clinical trials in breast cancer International Day of Clinical Trials
INFARMED (Lisboa, Portugal)
2017/03 Breast Cancer Update 2016 Update for Practicing Oncologists
European Society of Medical Oncology (Lisboa, Portugal)
2017/03 Predictive value of breast cancer immune features in response to neoadjuvant chemotherapy Inflammation Symposium
Centro de Estudos de Doenças Crónicas (CEDOC) (Lisboa, Portugal)
2017/03 Inovação em Oncologia Reunião Anual Sociedade Portuguesa Enfermagem Oncológica
Hospital de Braga (Braga, Portugal)
2016/11 Are we ready for a National Molecular Screening Platform in metastatic breast cancer Reunião SOLTI Portugal
Grupo Cooperativo Ibérico de Ensaios Clínicos em Carcinoma da Mama
2016/11 O programa de ensaios clínicos do Instituto CUF de Oncologia, Investigação Clínica: do compromisso à ação Reunião Apifarma
2016/10 Young Oncologists Career Management Session: Practicing Oncologist
European Society for Medical Oncology
2016/10 ESMO Lounge Session: How I use and access ESMO resources
European Society for Medical Oncology
2016/10 ESMO Lounge Session: Practicing Oncologists Committee
European Society for Medical Oncology
2016/10 Interview for Oncology PRO: Trastuzumab Biosimilars
European Society for Medical Oncology
2016/10 Breast Cancer Neoadjuvant Trials as a model to study drug resistance iMED genetics workshop
NOVA Medical School
2016/10 Espiritualdade e cancro
Instituto CUF de Oncologia
2016/07 Update in Clinical Oncology
Instituto CUF de Oncologia
2016/05 Fertilidade e Cancro Congresso dos Médicos Internos da José de Mello Saúde
Hospital de Braga
2016/03 Cancer and Inflammation Programa de Doutoramento da NOVA Medical School
Universidade NOVA de Lisboa
2016 Systemic therapy in Prostate Cancer
Hospital de Vila Franca de Xira
2016 Initiating the cancer genetic risk programme
Hospital Fernando da Fonseca
2015 Evaluation of symptoms of patients on palliative chemotherapy
St. Olavs Hospital (Trondheim) (Trondheim, Norway)
2015 What innovative tests should we use in breast cancer patients and why? Meeting of hospital cancer genomics programs
King Albert II Institute Cancerology and Hematology, Cliniques Universitaires Saint-Luc, UCL Bruxelles (Bruxelas, Belgium)
2015 Centrosome clustering in breast cancer Annual meeting Biomedical students,Universidade Algarve
Universidade do Algarve
2015 Hormonal replacement therapy in cancer survivors
Hospital de Vila Franca de Xira
2015 Developing breast cancer research in a clinical setting Anual Meeting Portuguese Senology Society
2015 Predictive and prognostic factors in early breast cancer Annual meeting Medical students, Universidade de Lisboa
2015 Initiation to research module: My PhD trajectory Nova Medical School, PhD Program
2015 Gynecological Oncology the view of the oncologist Annual Meeting Portuguese Society of Pathologists
2015 Cancer module - How I developed my PhD project Porto Medical School, MD-PhD Program
2015 Immunology module - Cancer immunology Lisbon Medical School, MD-PhD Program
2014 Biology of cancer bridging basic and translational research: Cytoskeletal dynamics in cancer Center for Genomic Regulation - EU Life Consortium Scientific Meeting
(Barcelona)
2014 When should we stop palliative chemotherapy European Society for Medical Oncology
European Society for Medical Oncology
2014 How to deliver bad news
Hospitais CUF Lisboa
2014 How to develop a research consortium - Our experience in H2020 Annual innovation meeting José de Mello group
2014 How to deliver bad news
Hospital CUF Porto
2014 Personalized cancer therapy Annual pharmaceutical sciences student retreat, Universidade do Porto
Universidade do Porto
2014 How to deliver bad news
Hospital Vila Franca de Xira
2014 Ethics in the end of life Encontros de Ciencia Viva, Universidade de Aveiro
Universidade de Aveiro
2014 Centrosome clustering in breast cancer Annual Meeting Portuguese Society of Oncology
2014 Shared session with Stein Kaasa on Building a H2020 research consortium to study palliative chemotherapy Encontro de Cuidados Paliativos Instituto Português de Oncologia Porto
Instituto Português de Oncologia Porto
2013 Chemotherapy in the end of life Annual meeting of the Galician Lung Cancer Society
(Vigo, Spain)
2013 Centrosome clustering is prognostic in early breast cancer Annual meeting of the Portuguese Society of Human Genetics
2013 Centrosome clustering is prognostic in early breast cancer Annual Gulbenkian PhD student retreat
2013 Highthroughput data module: How does a clinician do a PhD project in bioinformatics PhD Program
Lisbon Nova Medical School
2013 Initiating the cancer genetic risk programme
Hospital CUF Descobertas
2013 Neoadjuvant systemic treatment Annual Meeting of Portuguese Senology Society
2013 How to foster collaboration between clinicians and bench scientists Annual Breast Cancer Meeting of Centro Hospitalar Barreiro-Montijo
Hospital do Barreiro
2013 Chemotherapy in the end of life Palliative Care Meeting - Hospital CUF Porto
Hospital CUF Porto
2012 Investigação em Oncologia Jornadas de Carcinoma da mama do Hospital do Barreiro
Hospital do Barreiro
2011 Heterogeneidade do carcinoma da mama triplo negativo Reunião anual Astra Zeneca
Astra Zeneca
2011 Centrosome clustering is prognostic in early breast cancer Annual meeting of the Portuguese Society of Human Genetics
2010 Are all aromatse inhibitors created equal? European breast cancer conference
(Barcelona, Spain)
2009/01 Cancro da Mama: Diagnóstico e terapêutica 4ª Reunião de cancro da mama do Serviço de Oncologia, Hospital do Barreiro
Hospital do Barreiro (Barreiro, Portugal)
2009 Terapêutica Neoadjuvante Congresso Nacional de Senologia
(Portugal)
2008 Terapêutica endócrina em Carcinoma da Mama Encontros de Oncologia do Serviço de Oncologia Hospital de Évora
Hospital de Évora (Évora, Portugal)
2007 Tales of targeted therapy: Sunitinib First Iberic Meeting on Medicinal Chemistry: Anticancer Agents
(Peso da Régua, Portugal)
2006 The MINDACT patient DVD MINDACT investigator meeting
European Breast Cancer Conference (Nice, France)
2006 Tailoring of systemic therapy in early stage breast cancer: Any progress? Apresentação oral, XVII International Congress of Anti-Cancer Treatment
2005 Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself Congresso da Sociedade Belga de Oncologia Ginecológica
2004/05 Percurso dos doentes oncológicos num Serviço de Medicina Interna
X Congresso Nacional de Medicina Interna (Vilamoura, Portugal)
2001/05 Infecções fúngicas num Serviço de Medicina VII Congresso Nacional de Medicina Interna
(Vilamoura, Portugal)

Supervision

Thesis Title
Role 		Degree Subject (Type)
Institution / Organization
2017 - 2021 Histopathological Prognostic Factors in Colon Retal Cancer After Curative Surgery - A 5 years Follow-Up
Co-supervisor
 Doctoral Programme in Medicine (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2016 - 2020 Translating Breast Cancer Immune Features into Biomarkers and Therapies
Co-supervisor
 International Doctoral Programme in Health Sciences (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2016 - 2020 Differential molecular signature in patients from African origin with Triple-Negative Breast Cancer
Co-supervisor
 International Doctoral Programme in Health Sciences (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2017 - 2018 Avaliação da Expressão de PD-L1 e de Subpopulações Linfocitárias em Cancro da Mama
Supervisor
 Mestrado em Oncobiologia e Mecanismos Moleculares do Cancro (Master)
Universidade do Algarve, Portugal
2017 - 2018 Utilização de Imunohistoquímica para Avaliação da Densidade Linfática no Mesentério de Adenocarcinomas do Cólon
Supervisor
 Mestrado em Oncobiologia e Mecanismos Moleculares do Cancro (Master)
Universidade do Algarve, Portugal
2015 - 2016 Expression of matrix gla protein (MGP) in breast cancer: a molecular and cellular approach
Co-supervisor
 Mestrado em Oncobiologia
2014 - 2015 Towards direct transdifferentiation of adult human cells to the pancreatic ß-cell fate
Co-supervisor
 Mestrado em Ciências Biomédicas
Universidade do Algarve, Portugal

Event participation

Activity description
Type of event 		Event name
Institution / Organization
2024/09 - Current Presentation of the Television Program "Vamos falar de Cancro?" from the Saúde+TV
2020 - Current Presentation of the Television Program "Histórias Clínicas" from the Saúde+TV

Association member

Society Organization name Role
2017 - Current European Medicines Agency
2015 - Current European Society Medical Oncology Oncology PRO Working group and Practicing Oncologists’ Committee
2014 - Current European Society Medical Oncology Practicing Oncologists Committee
2013 - Current European Society Medical Oncology Examination Working Group and Publishing Group
2008 - 2009 Member national panel on consensus in triple negative and lobular breast cancer - Portuguese Senology Society
2007 - 2009 Secretary of the breast group in National Comission for Oncological Disease - Ministry of health
2006 - 2007 Medical advisor - Pfizer

Journal scientific committee

Journal title (ISSN) Publisher
2011 - Current Annals of Oncology (1569-8041) Elsevier
Distinctions

Award

2025 Targeting Immunosuppressive Neutrophils: Unlocking new pathways in Immune Oncology to improve Triple Negative Breast Cancer treatments
Gilead Génese, Portugal
2025 Personalizing immunotherapy for high-risk early-stage triple negative Breast cancer by targeting immunosuppressive neutrophils
Liga Portuguesa Contra o Cancro, Portugal
2023 CaixaImpulse Innovation Grant 2023
Fundação 'la Caixa', Portugal
2020 Scicare Novartis Health Science Accelerator
Novartis Farma SA, Portugal
2019 Terry Fox Award - Dissecting the predictive and therapeutic value of HLA-DR-expressing cytotoxic T lymphocytes in Breast Cancer
Liga Portuguesa Contra o Cancro, Portugal
2019 Pfizer Award - HLA-DR in Cytotoxic T Lymphocytes Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Pfizer Portugal, Portugal
2018 Tagus Tank Consortium - HLA-DR in Cytotoxic T Lymphocytes Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Tagus Tank Consortium, Portugal
2016 Leaders Generation Programme
European Society for Medical Oncology, Switzerland
2016 Development of therapeutics targeting Notch1 ligands Delta-like1 and Jagged2
iNOVA4Health, Portugal
2016 Searching for positive markers in triple negative breast cancer
iNOVA4Health, Portugal
2014 Norwegian National Science Foundation - Collaborative research grant: Cancer Care in the End of Life
2014 Collaborative grant Centrosome abnormalities in breast cancer
Fundação para a Ciência e a Tecnologia, Portugal
2014 Collaborative research grant: Notch ligands in Triple Negative Breast Cancer
Fundação para a Ciência e a Tecnologia, Portugal
2013 QREN Award - Generating patient derived effector cells in breast cancer patients
2013 Immunotherapy in breast cancer
Bluepharma, Portugal

Other distinction

2012 Terry Fox Award - Centrosome abnormalities in breast cancer
Liga Portuguesa Contra o Cancro, Portugal
2011 Award for best presentation at the annual meeting of Gulbenkian Students
Instituto Gulbenkian de Ciência, Portugal
2008 3rd place: Consultation of family risk of breast and ovary, IPO Lisboa
2008 Advanced medical education program
Fundação Calouste Gulbenkian, Portugal

Fundação Champalimaud, Portugal